Clinical Trials Logo

Methylmalonic Acidemia clinical trials

View clinical trials related to Methylmalonic Acidemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03484767 Completed - Propionic Acidemia Clinical Trials

"The MaP Study": Mapping the Patient Journey in MMA and PA

Start date: March 20, 2018
Phase:
Study type: Observational

Longitudinal, exploratory, natural history study of patients with MMA due to mut deficiency and PA to characterize the changes in blood disease biomarkers over time and the frequency and severity of clinical events related to their disease.

NCT ID: NCT02426775 Completed - Propionic Acidemia Clinical Trials

Carglumic Acid in Methylmalonic Acidemia and Propionic Acidemia

CAMP
Start date: November 2015
Phase: Phase 3
Study type: Interventional

A Phase IIIb (Three b), Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carglumic Acid (Carbaglu®) in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA). Carbaglu® clinical experience in Organic Acidemia (OA) is limited to a non-comparative retrospective collection of data from patients who had received Carbaglu® for 1 to 15 days. There is no current evidence supporting the use of carglumic acid for the chronic management of patients with OA. The investigators are proposing a randomized multicentre prospective clinical trial to evaluate long-term effects of the use of Carbaglu® (50mg/kg/day) combined with standard chronic therapy in patients with PA and MMA compared to standard chronic therapy alone.

NCT ID: NCT01599286 Completed - Clinical trials for Methylmalonic Acidemia

Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia

STO
Start date: September 1, 2012
Phase: Phase 2
Study type: Interventional

The overall objective of this drug trial is to determine whether the treatment of acute hyperammonemia with N-carbamyl-L-glutamate (NCG, Carglumic acid) in propionic acidemia (PA), methylmalonic acidemia (MMA), late-onset CPS1 deficiency (CPSD) and late-onset Ornithine transcarbamylase deficiency (OTCD) accelerates the resolution of hyperammonemia efficiently and safely. The primary goal is to determine if the study drug (NCG) efficiently reduces ammonia levels following a hyperammonemia episode(s). Secondly, the investigators want to know if treatment with this study drug (NCG) efficiently improves neurologic function, reduces plasma glutamine levels and lessens the duration of hospitalization after each episode of hyperammonemia.